Background: Natriuretic peptides have actions likely to ameliorate cardiac dysfunction. B-
type natriuretic peptide (BNP) is indicated as treatment for decompensated cardiac failure …

Methods: MI was induced by coronary ligation in rats and confirmed by echocardiography.
19 rats were randomized to 1 of 3 groups: sham (n= 7), MI+ saline (n= 5), MI+ BNP (400 ng …

Cardiac Ischemia is an important trigger for the release of B-type natriuretic peptide (BNP).
BNP and N-terminal pro-BNP (N-proBNP) are emerging as important biomarkers for risk …

OBJECTIVE: The objective of this study is to determine the effect of nesiritide (human
recombinant BNP [hBNP]) in combination with standard therapy on the concentrations of B …

Animal studies have reported a cardioprotective effect for atrial natriuretic peptide (ANP) or
brain natriuretic peptide (BNP) administration in the setting of acute myocardial infarction …

The natriuretic hormones are a family of vasoactive peptides that can be measured
circulating in the blood. Because they serve as markers of hemodynamic stress, the major …

Background B-type natriuretic peptide (BNP) is a hormone with pleiotropic cardioprotective
properties. Previously in our non–placebo-controlled non-blinded pilot study (BELIEVE) in …

Background: B-type natriuretic peptide (BNP, nesiritide) has anti-fibrotic, anti-hypertrophic,
anti-inflammatory, vasodilating, lusitropic and aldosterone-inhibiting properties but …

B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (N-proBNP)
are released from the heart in response to increased wall stress. Assays for these peptides …

Background: An increase in circulating B‐type natriuretic peptide (BNP) is associated with a
poor outcome in patients with acute heart failure. The primary aim of this study was to …